Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1987-08-26
1988-07-19
Robinson, Allen J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514824, A61K 3150
Patent
active
047585692
ABSTRACT:
This invention relates to the use of doxazosin or a pharmaceutically acceptable acid addition salt thereof as an agent for retarding the development of atherosclerosis in a mammal, especially for reducing atherosclerotic plaque involvement and for retarding and reducing both the fibrosis and lipid deposition of developing atherosclerotic plaques associated with atherosclerosis.
REFERENCES:
patent: 4130647 (1978-12-01), Taylor
patent: 4188390 (1980-02-01), Campbell
patent: 4361564 (1982-11-01), Edwards
patent: 4532135 (1985-07-01), Edwards
patent: 4582832 (1986-04-01), Swindell
Swindell, A. C. et al., Effects of Doxazosin on Diet-Induced Hypercholesterolemia in C57BR/cdJ Mice, Am. J. Cardiology 59: 29G-34G, 1987.
Woodside, W. F. et al., Effects of .alpha..sub.1 -Inhibition on Lipid Metabolism in the Rat. J. Cardiovascular Pharmacology 10 (Suppl. 9): S-27-S34, 1987.
Benson Gregg C.
Frost Albert E.
Pfizer Inc.
Richardson Peter C.
Robinson Allen J.
LandOfFree
Doxazosin as an anti-atherosclerosis agent does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Doxazosin as an anti-atherosclerosis agent, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Doxazosin as an anti-atherosclerosis agent will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-597430